688505 Stock Overview
Engages in the research, development, manufacture, and sale of bio-pharmaceutical products primarily in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 1/6 |
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$8.52 |
| 52 Week High | HK$10.61 |
| 52 Week Low | HK$6.11 |
| Beta | 0.21 |
| 11 Month Change | 0.24% |
| 3 Month Change | 27.16% |
| 1 Year Change | -18.93% |
| 33 Year Change | -39.83% |
| 5 Year Change | n/a |
| Change since IPO | -50.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| 688505 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -8.4% | -6.0% | -6.7% |
| 1Y | -18.9% | -7.9% | 1.9% |
Return vs Industry: 688505 underperformed the CN Pharmaceuticals industry which returned -7.9% over the past year.
Return vs Market: 688505 underperformed the CN Market which returned 1.9% over the past year.
Price Volatility
| 688505 volatility | |
|---|---|
| 688505 Average Weekly Movement | 9.1% |
| Pharmaceuticals Industry Average Movement | 7.2% |
| Market Average Movement | 8.2% |
| 10% most volatile stocks in CN Market | 12.5% |
| 10% least volatile stocks in CN Market | 5.5% |
Stable Share Price: 688505 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 688505's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 913 | Da Jun Zhao | www.fd-zj.com/DesktopModules/HT/chinese/home/Index.aspx |
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the research, development, manufacture, and sale of bio-pharmaceutical products primarily in China. It offers genetic engineering platform drugs, including CD30-DM1 antibody-drug conjugate (ADC), which is in Phase I clinical trials for tumors; Trop2-SN38 ADC that is in Phase I clinical trials for triple negative, breast, bladder, gastric, and other tumors; Trop2-BB05 ADC that is in pre-clinical studies for lung cancer and triple negative breast cancer; DLL3-BB05 ADC that is in pre-clinical trials for tumors; and HER2 ADC that has carried out phase I clinical study for metastatic breast and gastric cancers. The company also provides photodynamic technical platform drugs, such as hemoporfin for port wine stain, which is in Phase IV clinical trial; and aminolevulinic acid, which is in Phase II clinical trials for cervical diseases infected by HPV and acne, as well as completed pre-clinical study for brain gliomas.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Fundamentals Summary
| 688505 fundamental statistics | |
|---|---|
| Market cap | CN¥6.87b |
| Earnings (TTM) | CN¥105.20m |
| Revenue (TTM) | CN¥691.62m |
24.7x
P/E Ratio3.7x
P/S RatioIs 688505 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688505 income statement (TTM) | |
|---|---|
| Revenue | CN¥691.62m |
| Cost of Revenue | CN¥64.16m |
| Gross Profit | CN¥627.46m |
| Other Expenses | CN¥522.25m |
| Earnings | CN¥105.20m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.10 |
| Gross Margin | 90.72% |
| Net Profit Margin | 15.21% |
| Debt/Equity Ratio | 0% |
How did 688505 perform over the long term?
See historical performance and comparison